Touchlight, a pioneering leader in synthetic DNA technology, is pleased to announce the appointment of Will Downie as a key adviser to support its mission in advancing genetic medicines. Downie’s ...

Frespaciguat is under clinical development by Merck and currently in Phase II for Pulmonary ... It is administered through inhalation route. The drug candidate acts by targeting soluble guanylate ...

Frespaciguat is under clinical development by Merck and currently in Phase III for Idiopathic ... It is administered through inhalation route. The drug candidate acts by targeting soluble guanylate ...

The compound can then be delivered through injection, infusion, inhalation, or ingestion ... also experiencing a surge of interest, antibody-drug conjugates (ADCs). However, there is a difference ...

Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare ...

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks ... awarded as an incentive to carry out drug development for a rare paediatric disease, that can be used to reduce ...

After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

the best-selling drug in the world, to decline in the coming years? And can they trust Merck’s guidance on that decline? The problems with Gardasil relate entirely to sales of the vaccine in ...

Merck achieved revenue growth in Q4, but stocks tumbled Tuesday amid news that the company is pausing Gardasil shipments to China. © 2024 Fortune Media IP Limited ...

On Monday, Germany-based Merck KGaA (OTC:MKGAF ... have the potential to help counter revenue losses from expiring drug patents and increased competition. Price Action: SWTX stock is down ...